No abstract available
Keywords:
biomarker; diagnostic tools; hypoxic-ischemic encephalopathy (HIE); neonatal brain injury; neonatal encephalopathy (NE); prognostic indicators.
PubMed Disclaimer
Conflict of interest statement
SW is Chief Medical Officer and co-founder of Neopredix, a spin-off of the University of Basel, Switzerland. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
-
Norman M, Hallberg B, Abrahamsson T, Bjorklund LJ, Domellof M, Farooqi A, et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004–2007 and 2014–2016. JAMA. (2019) 321(12):1188–99. 10.1001/jama.2019.2021
-
DOI
-
PMC
-
PubMed
-
-
Pierrat V, Marchand-Martin L, Marret S, Arnaud C, Benhammou V, Cambonie G, et al. Neurodevelopmental outcomes at age 5 among children born preterm: epipage-2 cohort study. Br Med J. (2021) 373:n741. 10.1136/bmj.n741
-
DOI
-
PMC
-
PubMed
-
-
McIntyre S, Nelson KB, Mulkey SB, Lechpammer M, Molloy E, Badawi N, et al. Neonatal encephalopathy: focus on epidemiology and underexplored aspects of etiology. Semin Fetal Neonatal Med. (2021) 26(4):101265. 10.1016/j.siny.2021.101265
-
DOI
-
PubMed
-
-
Wassink G, Harrison S, Dhillon S, Bennet L, Gunn AJ. Prognostic neurobiomarkers in neonatal encephalopathy. Dev Neurosci. (2022) 44(4–5):331–43. 10.1159/000522617
-
DOI
-
PubMed